Quick Answer
Bioventus Inc. reported Long Term Debt of $278.95 million for the year ending 2025.
- Bioventus Inc. showed a decrease of -9.5% in Long Term Debt from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $169.73 million | Q2 2021: $166.08 million | Q3 2021: $162.44 million | Q1 2022: $348.04 million | Q2 2022: $351.43 million | Q3 2022: $393.10 million | Q1 2023: $404.27 million | Q2 2023: $374.57 million | Q3 2023: $375.03 million | Q1 2024: $355.43 million | Q2 2024: $344.72 million | Q3 2024: $345.02 million | Q1 2025: $308.59 million | Q2 2025: $297.88 million | Q3 2025: $311.33 million.
- Over the full 6 years of available data (2020 to 2025), Bioventus Inc.'s Long Term Debt has grown by 60.9%.
- Historical annual values: Fiscal year 2025: $278.95 million | Fiscal year 2024: $308.29 million | Fiscal year 2023: $367.00 million | Fiscal year 2022: $385.01 million | Fiscal year 2021: $339.64 million | Fiscal year 2020: $173.38 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: